Melanotan II (MT-II) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that promotes skin pigmentation, enhances libido, and may reduce appetite. Developed in the 1980s at the University of Arizona during skin cancer research, MT-II was designed to mimic α-MSH and stimulate the body's natural tanning response for UV protection.
Primary reported benefits include:
- Accelerated and deeper skin tanning with minimal UV exposure
- Enhanced erectile function and sexual arousal
- Appetite suppression and potential fat loss support
- Possible protective effects against UV-induced skin damage
What Is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s as part of skin cancer prevention research. Researchers sought to stimulate the body's natural tanning response — melanogenesis — as a photoprotective mechanism against UV-induced DNA damage.
MT-II is distinguished from its predecessor, Melanotan I (afamelanotide), by its broader receptor activity. While Melanotan I acts primarily at the MC1R receptor to influence pigmentation, MT-II binds MC1R, MC3R, MC4R, and MC5R subtypes. This broader receptor profile extends its effects beyond tanning to include sexual function and appetite regulation, making it pharmacologically distinct from Melanotan I.
MT-II has been colloquially called the "Barbie drug" in media coverage, a term originating in tabloid reporting rather than any scientific or regulatory designation.
How It Works
Melanocortin Receptor Activation
Upon subcutaneous injection, MT-II enters systemic circulation and binds to melanocortin receptors. The MC1R receptor on melanocytes mediates the primary tanning response. Binding triggers cyclic adenosine monophosphate (cAMP) signaling, which stimulates tyrosinase activity and increases eumelanin production — the brown-black pigment responsible for darker skin tone. This mechanism produces a more sustained and deeply pigmented tan compared to UV exposure alone.
Sexual Function Enhancement
MC4R receptors in the hypothalamus and central nervous system mediate the pro-sexual effects of MT-II. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, MT-II works centrally to initiate arousal through dopaminergic pathways. This central mechanism of action is what led to the development of bremelanotide (PT-141), a related melanocortin peptide that received FDA approval for hypoactive sexual desire disorder in women.
Appetite and Energy Regulation
MC3R and MC4R receptors in the hypothalamus play a role in regulating feeding behavior and energy balance. Research demonstrates that MT-II activation at these receptors reduces food intake and may influence fat metabolism, contributing to the appetite suppression commonly reported by users.
Pharmacokinetics
Peak plasma concentrations occur within 1–2 hours post-injection. MT-II has a half-life of approximately 1–2 hours. Despite this relatively short plasma half-life, biological effects on melanogenesis persist longer due to sustained melanin production in melanocytes once the signaling cascade has been initiated.
Dosage Protocols
No FDA-approved dosing guidelines exist for MT-II. The following protocols are derived from clinical research and community reports:
Loading Phase:
- Initial dose: 0.1 mg (for tolerance assessment)
- Escalating to 0.25 mg daily for 2–4 weeks. The Phase I trial (Dorr et al.) tested doses up to 0.025 mg/kg, which corresponds to approximately 0.2 mg for an 80 kg individual
Maintenance Phase:
- 0.5–1 mg once or twice weekly after desired pigmentation is achieved
UV Exposure: MT-II enhances the tanning response but does not eliminate the need for sun or sunbed exposure. Users typically combine the peptide with 10–20 minutes of UV exposure. MT-II does not provide complete UV protection and should not be used as a substitute for sunscreen.
Cycling: Some users implement 4–8 week breaks after 3–6 month periods to maintain receptor sensitivity, though clinical data supporting specific cycling protocols is limited.
How to Use / Administration Methods
MT-II is administered via subcutaneous injection into abdominal fat, the thigh, or the deltoid region. It is supplied as a lyophilized powder requiring reconstitution before use.
Injection Procedure:
- Clean the injection site with an alcohol swab
- Pinch a skin fold to isolate subcutaneous tissue
- Insert needle at a 45–90 degree angle
- Inject solution slowly
- Withdraw the needle and apply gentle pressure
Insulin syringes (29–31 gauge, 0.5–1 mL) are commonly used for administration. Rotating injection sites is recommended to prevent lipodystrophy.
Nasal spray formulations exist but have significantly lower and less predictable bioavailability than subcutaneous injection, and are generally not favored by experienced users.
Results Timelines
Week 1:
- Facial flushing, mild nausea, and increased libido are possible
- Minimal visible tanning without UV exposure
- Side effects tend to be most pronounced during this initial period
Weeks 2–3:
- Enhanced tanning response becomes visible with UV exposure
- Existing freckles and moles may darken rapidly
- Sexual function effects are typically well established by this point
Weeks 4–6:
- Significant pigmentation changes develop
- Tan appears more natural and even, with a "golden" or "bronze" quality described by many users
- Appetite suppression effects may become more noticeable
Maintenance Period:
- Pigmentation is maintained with weekly dosing and periodic UV exposure
- Without maintenance dosing, the enhanced tan fades over 1–3 months as melanin-containing keratinocytes are shed during normal skin renewal
Individual response varies based on skin type (Fitzpatrick scale), frequency of UV exposure, and genetic factors affecting melanocortin receptor sensitivity.
Research Evidence
Phase I Clinical Trial (Life Sciences, 1996): Dorr et al. confirmed that MT-II produced significant skin pigmentation increases in humans with minimal UV exposure, establishing dose-dependent tanning effects and a basic safety profile in a pilot human study.
Erectile Dysfunction Research (Journal of Urology, 1998): Wessells et al. demonstrated that MT-II produced erections in men with psychogenic erectile dysfunction in a double-blind, placebo-controlled crossover study. This research supported the central mechanism of action and directly contributed to the development of bremelanotide (PT-141), which was later FDA-approved for hypoactive sexual desire disorder in women.
Melanocortin Receptor Pharmacology: Studies by Hruby et al. and others elucidated MT-II's receptor binding profile and downstream effects across physiological systems, informing the understanding of both its therapeutic potential and side effect profile.
Animal Studies: Preclinical research demonstrated appetite-suppressing effects of melanocortin receptor agonists, including MT-II. Human body composition data on MT-II specifically remains limited, and animal findings have not been replicated in controlled human trials.
Review Evidence: A 2019 review in Dermatology Online Journal by Brennan et al. assessed the available evidence for MT-II efficacy and safety, noting the gap between preclinical promise and the absence of phase II/III clinical trial data for any indication.
Stacking
MT-II with PT-141 (Bremelanotide)
Some users alternate between MT-II for tanning and PT-141 for sexual function enhancement, as PT-141 lacks significant tanning effects. PT-141 is FDA-approved for hypoactive sexual desire disorder in women, giving it a different legal and safety profile. These two peptides should not be used simultaneously due to overlapping receptor activity.
MT-II with Growth Hormone Secretagogues
Bodybuilders occasionally combine MT-II with ipamorelin or CJC-1295 for multiple cosmetic and body composition goals. No synergistic interaction between MT-II and growth hormone secretagogues has been established in research.
MT-II in Cutting Phases
Some users incorporate MT-II into cutting or body recomposition phases alongside other compounds, citing its mild appetite suppression. However, its contribution to fat loss as a standalone mechanism is considered modest and is not supported by dedicated human trials.
Reconstitution, Storage & Prep
MT-II is supplied as sterile lyophilized powder, typically in 10 mg vials.
Reconstitution Process:
- Allow vial to reach room temperature
- Using a sterile syringe, draw bacteriostatic water (preferred) or sterile water
- Inject water slowly down the inside wall of the vial — do not spray directly onto powder
- Gently swirl (do not shake) until fully dissolved
- The solution should be clear and colorless; do not use if cloudy or particulate matter is visible
Common Reconstitution Ratio:
- 2 mL bacteriostatic water added to a 10 mg vial yields 5 mg/mL (500 mcg per 0.1 mL / 10 units on an insulin syringe)
Storage Guidelines:
- Unreconstituted powder: Refrigerate (2–8°C) or freeze; stable for 12+ months
- Reconstituted solution: Refrigerate at 2–8°C and use within 4–6 weeks
- Protect from light; avoid repeated freeze-thaw cycles
- Do not use if solution appears cloudy or contains visible particles
Side Effects
Common Side Effects:
- Nausea (most frequent, especially with initial doses)
- Facial flushing and warmth
- Fatigue or drowsiness
- Appetite suppression
- Spontaneous or prolonged erections in men
Less Common Side Effects:
- Darkening of existing moles and freckles
- Development of new nevi (moles)
- Injection site reactions (redness, pain, swelling)
- Headache
- Dizziness
Concerns Requiring Attention:
Mole darkening raises theoretical melanoma concerns due to MT-II's direct stimulation of melanocytes. While direct causality between MT-II use and melanoma has not been established in clinical studies, those with numerous atypical moles, a personal or family history of melanoma, or very fair skin (Fitzpatrick type I) should exercise caution. Regular dermatological monitoring is advisable for anyone using MT-II.
Rare cases of priapism — a prolonged, painful erection lasting more than 4 hours — have been reported in men using MT-II. Priapism constitutes a medical emergency requiring immediate attention, as delayed treatment can result in permanent erectile dysfunction.
Products sourced from unregulated channels may vary significantly in purity, potency, and sterility, introducing additional safety risks independent of the compound itself.
Legal Status / FDA
MT-II is not approved by the FDA or equivalent regulatory bodies for any medical indication. The FDA has issued warnings regarding MT-II products sold online, citing concerns about safety, purity, and unsubstantiated health claims.
In the United States, MT-II occupies a legal gray area. It is not classified as a controlled substance, but selling it for human consumption violates FDA regulations. It is commonly sold as a "research chemical" not intended for human use, a designation that does not confer safety or quality assurances.
International Regulatory Status:
- Australia: Schedule 4 prescription-only medicine; unauthorized sale is prohibited
- United Kingdom: Not approved; sale for human consumption is illegal under medicines regulations
- European Union: Not authorized; subject to individual member state regulations
Sports / WADA
The World Anti-Doping Agency (WADA) included MT-II on its Prohibited List under peptide hormones and releasing factors (category S2). MT-II is banned both in-competition and out-of-competition.
Athletes subject to drug testing should be aware that MT-II and its metabolites are detectable through standard anti-doping protocols. The detection window varies based on dosing patterns and individual metabolism, potentially extending several days to weeks after the last administration.
Several athletes have received sanctions for MT-II use, and the compound should be considered a high-risk substance for any athlete competing under WADA-affiliated organizations.
Conclusion
Melanotan II represents a pharmacologically active peptide with documented effects on skin pigmentation and sexual function. Its melanocortin receptor activation mechanism is well-characterized, and limited clinical research supports efficacy for tanning enhancement. The development of bremelanotide from MT-II research demonstrates that its underlying science has real translational value.
However, MT-II's unapproved status means users assume full responsibility for sourcing, dosing, and monitoring for adverse effects. The absence of phase II or III clinical trial data for tanning or other indications leaves significant gaps in the long-term safety profile. Those considering use should weigh cosmetic benefits against the lack of long-term safety data, potential side effects including mole changes and priapism risk, and legal considerations in their jurisdiction. Regular skin examinations and awareness of warning signs remain prudent for any user.